Johnson & Johnson Late-Breaking Results Show Nipocalimab Significantly Reduced Systemic Lupus Erythematosus Disease Activity in a Phase 2 Study
June 04, 2026
June 04, 2026
RARITAN, New Jersey, June 4 -- Johnson and Johnson Innovative Medicine issued the following news release on June 3, 2026:
* * *
Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study
* Nipocalimab - the first and only neonatal Fc receptor (FcRn) blocker to be studied in systemic lupus erythematosus - is designed to target and reduce pathogenic immunoglobulin G . . .
* * *
Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study
* Nipocalimab - the first and only neonatal Fc receptor (FcRn) blocker to be studied in systemic lupus erythematosus - is designed to target and reduce pathogenic immunoglobulin G . . .